GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
0.424
-0.045 (-9.65%)
Mar 9, 2026, 4:00 PM EDT - Market closed
GT Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 8.95 | 8.57 | 7.11 | 12.45 | 47.92 | |
| Research & Development | 3.47 | 5.8 | 6.47 | 8.81 | 9.59 | |
| Operating Expenses | 12.42 | 14.36 | 13.58 | 21.26 | 57.52 | |
| Operating Income | -12.42 | -14.36 | -13.58 | -21.26 | -57.52 | |
| Interest Expense | -0.13 | - | -0.21 | -0.01 | -0.72 | |
| Interest & Investment Income | 0.12 | 0.4 | 0.78 | 0.29 | 0.04 | |
| Other Non Operating Income (Expenses) | -16.93 | 0.8 | 4.82 | 0.12 | 0.21 | |
| EBT Excluding Unusual Items | -29.35 | -13.16 | -8.19 | -20.85 | -57.98 | |
| Gain (Loss) on Sale of Investments | - | - | 0.05 | -0.03 | -0.03 | |
| Other Unusual Items | 1 | - | 0.55 | - | - | |
| Pretax Income | -28.35 | -13.16 | -7.6 | -20.88 | -58.01 | |
| Net Income | -28.35 | -13.16 | -7.6 | -20.88 | -58.01 | |
| Preferred Dividends & Other Adjustments | 6.1 | - | - | - | - | |
| Net Income to Common | -34.45 | -13.16 | -7.6 | -20.88 | -58.01 | |
| Shares Outstanding (Basic) | 6 | 2 | 1 | 1 | 1 | |
| Shares Outstanding (Diluted) | 6 | 2 | 1 | 1 | 1 | |
| Shares Change (YoY) | 190.57% | 40.78% | 26.87% | 13.18% | 542.06% | |
| EPS (Basic) | -6.25 | -6.94 | -5.64 | -19.66 | -61.81 | |
| EPS (Diluted) | -6.25 | -6.94 | -5.64 | -19.66 | -61.81 | |
| Free Cash Flow | -12.91 | -12.9 | -8.85 | -15.22 | -15.61 | |
| Free Cash Flow Per Share | -2.34 | -6.80 | -6.57 | -14.32 | -16.63 | |
| EBIT | -12.42 | -14.36 | -13.58 | -21.26 | -57.52 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.